Pfizer has announced top-line results from a second Phase 3 study evaluating the efficacy and safety of its oral JAK1 inhibitor, abrocitinib, in patients aged 12 or over with moderate to severe atopic dermatitis. The...
Latest articles
Indoco receives US FDA approval for Rasagiline tablets to treat Parkinson’s disease
Indoco Remedies Ltd. has received the final approval for its Abbreviated New Drug Application (ANDA) for Rasagiline 0.5 mg and 1 mg tablets from the United States Food & Drug Administration (FDA). Rasagiline is
FDA approves second PrEP drug to prevent HIV infection
The US FDA has approved Gilead’s Descovy (emtricitabine/tenofovir alafenamide) as a second pre-exposure prophylaxis (PrEP) drug in at-risk adults and adolescents weighing at least 75lbs for the prevention of HIV...
J&J steps forward in PARP prostate-cancer race with FDA breakthrough for Zejula
The FDA has granted breakthrough therapy designation for Johnson & Johnson’s Zejula in metastatic prostate cancer patients with certain gene mutations. But J&J is still facing a tough rival in Lynparza...
How to Score Your Content Assets for Long-Term Success
Want a balanced and actionable way to know if your content is doing what it’s supposed to do? Create a content scorecard. Here’s an easy-to-use format to evaluate your content quantitatively and qualitatively. Continue...
Novartis reports positive results from phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
Novartis announced that investigational, once─daily, inhaled QVM149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate or IND/GLY/MF) was superior to QMF149 (indacaterol acetate and mometasone furoate...
